Aduro BioTech Inc. announced on January 30, 2019, that it would be cutting its headcount by around 37%, shelving some of its pipeline programs and focusing all its resources on the discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways.
As a result of this company reset and the subsequent reduction in ongoing operating expenses, Aduro expects to extend its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?